Lantheus Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus or view top-rated stocks.

3 analysts have issued 1 year price targets for Lantheus' stock. Their LNTH stock forecasts range from $91.00 to $100.00. On average, they expect Lantheus' share price to reach $95.00 in the next year. This suggests a possible upside of 45.1% from the stock's current price.
View analysts' price targets for Lantheus or view top-rated stocks among Wall Street analysts.

Lantheus' stock was trading at $28.89 at the beginning of 2022. Since then, LNTH shares have increased by 126.5% and is now trading at $65.45.
View the best growth stocks for 2022 here.

Lantheus is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Lantheus.

Lantheus Holdings, Inc. (NASDAQ:LNTH) released its earnings results on Friday, April, 29th. The medical equipment provider reported $0.97 EPS for the quarter, topping the consensus estimate of $0.41 by $0.56. The medical equipment provider had revenue of $208.90 million for the quarter, compared to analysts' expectations of $165.30 million. Lantheus had a positive trailing twelve-month return on equity of 19.83% and a negative net margin of 6.89%. The company's quarterly revenue was up 125.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 EPS.
View Lantheus' earnings history.

Lantheus updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $2.90-$3.15 for the period, compared to the consensus EPS estimate of $2.05. The company issued revenue guidance of $800.00 million-$835.00 million, compared to the consensus revenue estimate of $711.56 million.

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lantheus include Ipsen (IPSEY), QuidelOrtho (QDEL), Intellia Therapeutics (NTLA), Ortho Clinical Diagnostics (OCDX), Neogen (NEOG), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Heska (HSKA), Alpha Teknova (TKNO), VolitionRx (VNRX), VolitionRx (VNRX), OncoCyte (OCX), MyMD Pharmaceuticals (MYMD) and Lucira Health (LHDX).
View all of LNTH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.54%), Vanguard Group Inc. (8.37%), State Street Corp (3.48%), Dimensional Fund Advisors LP (2.42%), Lord Abbett & CO. LLC (1.89%) and William Blair Investment Management LLC (1.77%). Company insiders that own Lantheus stock include Andrea Sabens, Brian A Markison, Carol Walker, Cesare Orlandi, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, Sam R Leno and Tudor Brown.
View institutional ownership trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, Russell Investments Group Ltd., Polar Asset Management Partners Inc., Peregrine Capital Management LLC, Bank of America Corp DE, The Manufacturers Life Insurance Company , and Reinhart Partners Inc.. Company insiders that have sold Lantheus company stock in the last two years include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus or view top insider-selling stocks.

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Lord Abbett & CO. LLC, Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Hood River Capital Management LLC, Penn Capital Management Company LLC, Assenagon Asset Management S.A., and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Lantheus or or view top insider-buying stocks.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LNTH stock can currently be purchased for approximately $65.45.

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.49 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71.28 million in net income (profit) each year or ($0.57) on an earnings per share basis.

Lantheus employs 612 workers across the globe.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for Lantheus is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.